Archives Advertise Editorial Calendar Subscribe Contact Us
Immunotherapy Shows Promise for TNBC Patients
By MELANIE KILGORE-HILL
FDA Approves Tecentriq® as First Immunotherapy Regimen for Breast Cancer
A breakthrough therapy is offering unprecedented hope to women with metastatic triple negative breast cancer (TNBC).
Last month, the FDA granted Genentech, a member of the Roche Group, accelerated approval to Tecentriq® (atezolizumab) plus chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC in people whose tumors express the protein PD-L1. The Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer, which represents a giant step forward in the treatment of a historically difficult-to-treat form of the disease.
Breast Cancer 101
Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, approximately 271,000 people in the United States will be diagnosed with breast cancer, and more than 42,000 will die from the disease in 2019.
Erika Hamilton, MD
Erika Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute and an IMpassion130 (Tecentriq) study investigator, said triple negative breast cancer, which accounts for 15 to 20 percent of breast cancers, is the most medically challenging to treat, partially because it tends to be more aggressive than more common types of the cancer.
Breast cancer can be diagnosed based on the presence or absence of three receptors - estrogen, progesterone and HER2. These receptors are the drivers for the development and growth of breast cancer. Triple negative breast cancer is diagnosed when a pathology report shows a negative result for all three of the common receptors.
While targeted therapies exist to decrease reoccurrence of hormonally-driven and HER2 breast cancers, patients with TNBC have historically received only chemotherapy. "The tricky thing about triple negative breast cancer is that we haven't had any targeted medications to treat it like we do for other types of breast cancer," Hamilton said.
"Triple negative is the worst prognosis, and women with metastatic TNBC typically have a survival rate of 18 months," she continued. "Biologically, it just tends to be more aggressive, and it's a more heterogeneous breast cancer group since all triple negatives aren't the same. They're a basket of cancers that don't express receptors, so it's been challenging to find a therapy that's effective for a large enough population."
Immunotherapy in Breast Cancer
Now, Hamilton and other oncologists are turning to atezolizumab - an immunotherapy already approved for treatment of certain lung and bladder cancers. Immunotherapy is a type of biological therapy that uses targeted drugs to convince the body's immune system to recognize that there is something foreign in the body (cancer) and to attack the cells threatening it.
Technically speaking, Tecentriq is a monoclonal antibody designed to bind with the protein PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells, which are essential for immunity.
During the Phase III IMpassion130 trial, which involved 902 participants, the IV therapy was administered in combination with the common chemotherapy drug nab-paclitaxel with notable results. Progression-free survival increased from 5 to 7.5 months, but what impressed Hamilton was that it translated into overall survival to a more significant degree.
The 41 percent of TNBC patients with the PD‑L1 protein, which helps cells hide from immune attack, extended life expectancy from 15.5 to 25 months. In fact, one TNBC trial participant under Hamilton's care is still working full-time three years after starting atezolizumab and no longer receives chemotherapy.
She said side effects of atezolizumab also make the therapy more appealing over chemo. "Day-to-day, it's tolerated really well, with no nausea or hair loss," Hamilton said, noting that some patients do experience fatigue or symptoms of immune activation, such as low-grade fever or body aches. "Compared to receiving chemo on a day-to-day basis, patients feel very good on it, and it's something you can stay on longer than chemo," she said.
A Genentech spokesperson said the company currently has several other large, ongoing studies of Tecentriq in TNBC, including early and advanced stages of the disease. In addition to Tecentriq, they're also studying the AKT-inhibitor ipatasertib in TNBC.
Sarah Cannon
NCI Release on FDA Approval
Bold Goals in Breast Cancer
Dr. Meredith McKean Brings New Hope, More Options for Melanoma Patients
When Basic Science Becomes a Breakthrough
Personalized Medicine & Lung Cancer
Bendell, MD, Johanna C.
Dr. Erika P. Hamilton: Making the 'C' Word a Little Less Scary for Breast & Gynecologic Cancer Patients
AMA Issues Checklist for the Transition to E/M Office Visit Changes
Wednesday, January 15, 2020 12:01 am
The American Medical Association (AMA) is helping physician practices integrate fundamental changes to the coding and documentation of evaluation and management (E/M) office visit services that account for nearly $23 billion in Medicare spending.
AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association
Monday, November 25, 2019 12:02 am
Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.
Tennessee Sees Fewer Infant Deaths In 2018
Friday, November 22, 2019 12:02 am
Infant Mortality Data Dashboard Now Available
Amedisys Expanding Commitment to End-of-Life Care for Veterans
Wednesday, November 20, 2019 12:02 am
Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year
AMA Applauds Relief from Documentation Burden in New Medicare Rule
Many physicians will have reduced documentation beginning in 2021
Oncology Innovation in Nashville
Monday, November 18, 2019 5:09 pm
From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.
Critical Insights into Nashville Health
For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.
Physician Spotlight: Leading with Compassion
Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.
The Oncology Care Model Value Proposition
The American Journal of Managed Care® hosts meetings across the country to help oncology practices understand and navigate the value-based care landscape at the intersection of quality and efficiency.
Tennessee Falling Short on Cancer-Fighting Public Policies
A 2019 ACS CAN report shows the state is falling short on public policies to fight cancer.
atezolizumab, Erika Hamilton, Immunotherapy, IMpassion130, Sarah Cannon Research Institute, Tecentriq®, TNBC, Triple Negative Breast Cancer
Reaction to Texas v. Azar Court Case Decision
Current Digital
InCharge 2020
InCharge Healthcare
New & Newsworthy
Alexander: Tightened Restrictions on Fentanyl Will Save Thousands of Tennesseans
Says bipartisan legislation passed by Senate extends the classification of all forms of illegal fentanyl in the most restrictive drug class, which China did last year after President Trump called on the Chinese President to stop the flow of fentanyl coming from China into the U.S.
The American Heart Association Launches #QuitLying Day to Combat Youth Vaping in Schools Across the Country
Local AHA awarded a grant to launch anti-vaping campaigns in two Middle Tennessee School Districts
Tennessee Blue Book 2019-2020 Edition Honors Women's Suffrage
The 2019-2020 edition of the Tennessee Blue Book, released this week, honors the 100th anniversary of the ratification of the 19th Amendment granting women the right to vote.
New Year, New Requirements: Pharmacy Technician Certification Board (PTCB) Launches New Certification Requirements and Updated Exam
Applicants must complete education and training or work experience to be eligible in 2020
Senate Confirms Hahn as FDA Commissioner
Senate health committee Chairman Lamar Alexander (R-Tenn.) said that "Dr. Stephen Hahn's experience as a practicing oncologist, a successful leader of the MD Anderson Cancer Center and work at the National Institutes of Health (NIH) make him the right leader for the FDA at this critical time."
2019 Women to Watch
Other Medical News Markets
Archives Arkansas
Subscribe Birmingham
Contact Us Memphis
Privacy Policy West TN
Log In to Nashville Medical News
Sign Ups for this site are currently unavailable.